Hepatitis b drug combo tested in phase 3 trial – but study stopped early
NCT ID NCT00823342
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two antiviral drugs, clevudine and tenofovir, alone or together, in 150 adults with chronic hepatitis B who had not been treated before. The goal was to see which approach worked best at controlling the virus after 96 weeks of treatment and 24 weeks of follow-up. The trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Clevudine and tenofovir (antiviral drugs)
- What this could lead to
- If successful, this could point toward a more effective treatment strategy for chronic hepatitis B, potentially reducing the need for lifelong medication.
- What could go wrong
- This trial was terminated early, so results are limited. The study is also small (150 participants) and only includes a specific subgroup of hepatitis B patients, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBE NEGATIVE CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Saint Joseph
Marseille, 13285, France